Tag
#HTGC
-
2026
-
Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS
-
Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS
-
Hercules Capital Named 2025 Americas BDC Manager of the Year by Private Debt Investor
-
Hercules Capital Named 2025 Americas BDC Manager of the Year by Private Debt Investor
-
HTGC – 8-K
-
HTGC – 10-K
-
Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results
-
HTGC – 8-K
-
Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029
-
Hercules Capital Announces New Supplemental Cash Distribution of $0.28 per Share
-
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Fourth Quarter 2025
-
HTGC – 424B2
-
HTGC – FWP
-
Hercules Capital Prices Institutional Notes Offering of $300.0 Million 5.350% Notes due 2029
-
HTGC – 424B2
-
HTGC – 8-K
-
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
-
Hercules Capital Announces Date for Release of Fourth Quarter and Full-Year 2025 Financial Results and Conference Call
-
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
-
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
-
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.